Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients

• Status: Recruiting
• Trial end date: 2020-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Virgin Coconut Oil (VCO) contains multiple compounds which have antibacterial, antiviral, and immunomodulatory properties. The role of VCO as an antivirus to treat COVID-19 requires further studies. A previous study has investigated the used of 30 ml of VCO to healthy volunteers for a month and reported no side effect. Here the investigators conduct a pilot trial to investigate the effect of VCO towards the clinical outcomes of COVID-19 patients in Indonesia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gadjah Mada University

Criteria

Inclusion Criteria:

• Adult patients, age ≥ 18 years old.

• COVID-19 patients diagnosed with nasopharyngeal/oropharyngeal PCR swab specimens that are treated in Central Public Hospital Dr. Sardjito, Teaching Hospital of Universitas Gadjah Mada (UGM), and Yogyakarta COVID-19 referral hospitals.

• Patients with mild and moderate pneumonia symptoms that are treated in Central Public Hospital Dr. Sardjito, Teaching Hospital of Universitas Gadjah Mada (UGM), and Yogyakarta COVID-19 referral hospitals.

Exclusion Criteria:

• Patients with liver function disorder.

• VCO hypersensitivity.

• Patients with severe pneumonia and/or Acute Respiratory Distress Syndrome (ARDS).

• Pregnant patients.

• Patients with malignant comorbidity.

• Critical or unconscious patients.

• Patients using other immunomodulators similar to VCO within less than three days before VCO administration.